Your browser doesn't support javascript.
loading
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger, Kathrin; De Filippi, Rosaria; Lindén, Ola; Viardot, Andreas; Hess, Georg; Lerch, Kristina; Neumeister, Peter; Stroux, Andrea; Peuker, Caroline A; Pezzutto, Antonio; Pinto, Antonello; Keller, Ulrich; Scholz, Christian W.
Affiliation
  • Rieger K; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. kathrin.rieger@charite.de.
  • De Filippi R; Department of Clinical Medicine and Surgery, Universita degli Studi di Napoli Federico II, Naples, Italy.
  • Lindén O; National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.
  • Viardot A; Lund University Hospital, Lund, Sweden.
  • Hess G; Department of Internal Medicine III, University Ulm, Ulm, Germany.
  • Lerch K; Johannes-Gutenberg-University, Mainz, Germany.
  • Neumeister P; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
  • Stroux A; Medical University Graz, Graz, Austria.
  • Peuker CA; Institute for Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Pezzutto A; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
  • Pinto A; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
  • Keller U; National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.
  • Scholz CW; Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Ann Hematol ; 101(4): 781-788, 2022 Apr.
Article in En | MEDLINE | ID: mdl-35150296
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yttrium Radioisotopes / Lymphoma, Follicular / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country: Germany Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Yttrium Radioisotopes / Lymphoma, Follicular / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country: Germany Country of publication: Germany